Literature DB >> 2276846

Immunoglobulin E responses and lung pathology resulting from aerosol exposure of calves to respiratory syncytial virus and Micropolyspora faeni.

L J Gershwin1, D L Dungworth, S R Himes, K E Friebertshauser.   

Abstract

Bovine respiratory syncytial virus (BRSV) infection of calves has been associated with a type-I hypersensitivity syndrome not unlike respiratory syncytial virus-associated pulmonary symptomatology in humans. To study the mechanism of pulmonary pathology in calves and define the relationship with both viral-specific IgE response and IgE titers to concurrent aerosol of Micropolyspora faeni (Mf) we subjected groups of calves to inhalation of Mf during acute BRSV infection. The calves were divided into 4 groups: exposed to virus only (group 1); exposed to aerosolized Mf over a 24-day period and then challenged with Mf during BRSV infection (group 2); similarly exposed to aerosolized Mf and then challenged with Mf without BRSV infection (group 3) and exposed to aerosolized Mf, infected with virus but not challenged with Mf (group 4). All calves were followed for appearance of IgE-specific responses to both BRSV and Mf, clinical disease expression, and pulmonary pathology including viral and allergen localization by immunohistology. Our data indicate an association of BRSV-specific IgE with increased development of lung pathology and clinical disease expression and an enhancing effect of aerosolized Mf on induction of virus-specific IgE. The presence of BRSV-specific IgE was solely in calves with the most significant macroscopic and microscopic pneumonic lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276846     DOI: 10.1159/000235192

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  1 in total

1.  Wheezing after the use of acetaminophen and or ibuprofen for first episode of bronchiolitis or respiratory tract infection.

Authors:  Paul Walsh; Stephen J Rothenberg
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.